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D Nef is an accessory protein of HIV-1 virus, which plays a critical role in the pathogenesis of AIDS. Nef augmer 
the HIV infection by dysregulating the immune system of the infected human(s). Nef is present on the surface of 
the infected cells and it is also secreted in exosomes (Nef-exosomes) into intracellular spaces. Nef exerts it 
p~th,Qg~ni9 .~ffE!ct§ ,. wh_eJ:L HJV:-l[Jf~ft§c!. 9§.1!? .QJ. N~f:~?'<~~9JI1.~~ .. ~orne into contac;twith un-infected (by-stander) 
cells. Through its interaction with host-cell's CXCR4 receptor, Nef induces ap'6ptosls, and aSci result, 'populatlon 
of immune cells drops with time. Immune dysregulatory effects of Nef can be inhibited by preventing Nef from 
interacting with host cells via antibody, peptides, or chemical compounds. 
The rationale of the proposed project was to identify the Nef motifs involved in the interaction with immune cells. 
We proposed to develop an antibody phage display library against Nef and use the library to identify Nef 
epitopes. 
The project was divided into two aims (Aim-1A1B and Aim 2) to be completed in three years' time. However, the 
project was funded for two years. We did manage to complete Aim-1A and Aim~1B within two years as 
proposed. Below is a summary of what has been achieved in the past two years. 
Aim-1: Identify the Nef Epitopes Exposed on the Surface of secreted Nef~vesicles and HIV 1~infected 
Cells. 
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Fig. 2.A. Prokaryotic expression vector pMXB-Hnef-6His. B. Expression 
and purification of Nef-6His from E. coli Bl21. M: BenchMark'M Pre-Stained 
Protein Ladder - 41llj Lane 1: Nef - purified from cobalt resin onlYj Lane 2: Nef - passed 
through chitin beads onlYj Lane 3: Nef- purified through chitin beads and cobalt resin. 
A. Production of monoclonal antibody phage 
library against HIV-1 Nef as screening tool to 
identify putative Nef motifs. 
Conventionally, monoclonal antibodies (MAbs) are 
generated from hybridoma cells (antibody secreting S-
cells fused with myeloma cells). Hybridoma generation 
is a time-consuming process and not suitable to 
generate libraries. Monoclonal Phage Display librarY 
(MPDL) is generated by harvesting antibody-encoding 
mRNA from the B-cells and then cloning these 
sequences to coat protein III of M13 phage. Resulting 
phages display 3-5 molecules of minimal antibody 
(single chain Fv) on their surface. A MPDL is composed 
of 1x107-1x1010 unique monoclonal antibodies. It is this huge diversity of 
MPDL that makes it a powerful tool to identify potential motifs. 
In order to develop anti-Nef MPDL, we first cloned the nef gene from HIV-1 
(NL4.3) virus into a mammalian vector called pQBI. This vector meant to be 
used for DNA immunization of the Balb/C mice. We also included a 6-His 
tag on C-terminal of the nef gene. We named this vector pQBI-Nef-6His 
(see Fig. 1). This resulted in the dual use of this vector, to immunize the 
mice, and to express and purify Nef in mammalian cells such as HEK293. 
For antibody screening purposes, we need a Nef-specific ELISA. Nef ELISA 
is not available commercially, so we developed our own. To develop Nef 
ELISA, the first step was to obtain highly purified Nef protein. Nef protein is 
available commercially but it is only 60-65% pure. Additionally, Nef protein 
is prone to self-aggregation· and has a short shelf-life. To develop a 
bacterial expression vector, we cloned the nef gene into the backbone of 
pMXB10 vector (NEB). In this vector, the nef-6His gene is 
expressed under the control of a T7 promoter. We named this 
vector pSA-HNef-6His (see Fig. 2A). Expression of HIV Nef in 
3 
bacterial host is challenging due to the presence of rare codons, E 2-
for which, the E. coli does not have tRNA. We solved this ~ 
problem by expressing nef gene in the presence of pACYC-RIL g 1-
plasmid, designed to provide tRNA for rare codons. With 
Fig 1. Eukaryotic vector pQBI-Nef-6His. 
• 
• 
• extensive optimization, we managed to produce up to 20mg/L of 
98% purified Nef (see Fig. 28) in E. coli (we are submitting a full 
length paper on this work). We have used the purified Nef to 
develop Nef-ELISA with a sensitivity of 50pg (see Fig. 3). 
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Fig. 3. Nef ELISA can detect as low as SOpg/mL Nef 
Next step was to immunize the animals. Our initial proposal was 
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Fig. 4. Antibody titer of mice Immunized with Nef 
to prime the animals with nef-encoding mammalian vector (pQBI-Nef) 
and boost with Nef.;exosomes. It proved difficult and very low· titers 
were obtained even after 6 boosts. We then decided to prime the 
animals with pQBI-Nef vector and boost with 1 aOug of purified Nef 
protein. This strategy worked, and we managed to obtain higher titers 
following 4 booster doses (see Fig. 4). Animals were sacrificed, and 
mRNA encoding MAb genes were harvested from the Trizol-treated 
spleens. The mRNA was converted into the cDNA by reverse 
transcription and variable heavy (VH) and light chain (VL) genes were 
amplified and assembled following SOE-PCR. The assembled genes 
were then cloned at SflllNotl in phage display vector called pHEN2. 
Ligated vector/insert was used to transform electrocompetent TG-1 
cells. Successful clones were selected on LB agar plates sup'plemented with Ampicillin. This concludes the 
cfu/mL. This gives ~s a moderate size library. 
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Next we screened the library for specific Nef binder phages. We 
coated the immuno-tubes with the purified Nef protein and added 
with phage library. Binder with no or low affinity were washed 
away by successive washes and phages with highest affinity for 
Nef were extracted (see Fig. 5). After each round of selection, 
the infected E. coli TG-2 cells were plated uniformly across the 
entire surface of selection agar plates. The plating of the bio- Fig. 5. Phage pools from the unpanned mouse anti-Nef 
scFv library stock and the phage pool obtained after 
panned library allowed every clone the opportunity to be subsequent rounds of panning were tested for binding to 
screened. This was important as some clones may grow slowly Nef by ELISA. 
than others due to the antibody toxicity within the bacteria. This L-...-..: ______________ --' 
affinity selection process allowed for enrichment of recombinant phage-scFv particles against the immobilized 
Nef. The phage pool contained a collection of recombinant ScFv with varying affinities for Nef and, therefore, 
individual clones were screened by ELISA to determine the binding patterns of the clones (see Fig.S). 
Clones 
Fig. 6. Fifty individual colonies were randomly selected 
and analyzed by Nef-ELISA. Eight (8) of the expressed 
clones showed significant binding to a Nef-coated ELISA 
plate suggesting a significant positive selection of phage-
scFv from the fourth round of 'biopanning'. 
Next we incubated select high-affinity-phages with increasing 
concentration of specific Nef peptides in individual reactions, and 
performed competitive binding experiments. Phages with affinity 
for a particular Nef peptide failed to bind to the immobilized Nef 
in the immuno-tubes and thus collected as unbound fraction. 
Unbound fraction was concentrated and expanded for future use. 
By this method, we identified ScFv-phages against ten 30-11" . 
Nef peptides overlapping 10 amino acids and spanning the em. 
206 amino acid Nef protein. Each binder was later confirmed for 
its specificity towards specific Nef epitope by competitive ELISA 
(see Fig.7). Selected binders were then propagated and 
sequenced. At this step of the project, we had obtained a 
repertoire of ScFv-phages able to recognize at least one of 10 Nef peptides across the entire 206 amino acids. 
All 10 ScFv clones were 
individually transformed into 
E.coli expression host (BL21-
DE3) and ScFv expressed and 
purified on Cobalt columns 
using I MAC (immobilized metal 
affinity chromatography). 
Purified ScFv were then 
conjugated with Biotin 
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(biotinylated ScFv) and used to 
identify Nef motifs in HIV-
infected Jurkat-T and THP-1 
monocytes and the secreted 
Nef-containing exosome-Iike 
vesicles from the infected cells. 
Fig. 7. Monoclonal phage inhibition ELISA was performed on a select anti-NefscFv clone in presence of 
10 peptides representing various Nef motifs. The phage were incubated for 1 hour with Nef peptides 
Ilg/mL, 1 Ilg/mL and 200 ng/mL) and added to a Nef-coated plate. Binding phage-scFv were detect .... 
using an anti-M13 HRP-Iabelled antibody. 
B. Identification of Nef epitopes exposed on the surface of HIV~1 infected cells amd secreted Nef 
vesicles. 
The next objective of the 
study was to use 
biotinylated ScFv and use 
them to identify Nef 
epitopes on the surface of 
infected cells and 
secreted exosomes. We 
infected Jurkat T-cells 
and THP1 monocytes 
with HIV-1 (NL4.3) and 
harvested the infected 
cells and culture 
supernatant containing 
Nef vesicles. Cells and 
vesicles were washed 
and treated individually 
with biotinylated ScFv, 
each specific to a 
particular Nef peptide (as 
determined previously by 
peptide binding assays). 
Following incubation, 
biotinylated ScFv were 
counter stained with anti-
biotin-FITC antibodies 
and subjected to flow 
cytometry analysis. Data 
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Fig. 8. Flowcytometric analysis of motif-specific ScFv binding to A. Jurkat-T cells; B. THP-1 monocytes; 
C. Nef-exosomes from Jurkat T cells; D. Nef-exosomes from THP-l monocytes. 
showed that ScFv bound to four (4) putative motifs of Nef present on the surface of HIV-1 infected Jurkat T cells 
and THP-1 monocytes. A motif comprised of amino acid sequence 'QEEEEVGFPV' appeared to be the most 
promising, since the mean fluorescence was highest for the ScFv targeted this region (see Fig. 8A & B). The 
pattern was consistent for both, HIV-1 infected Jurkat T cells and THP-1 monocytes. The ScFv bound to motifs 
IYKAAVDLSHF', 'WCYKLVPVEP', and 'NTSLLHPVSL' also resulted in higher mean fluorescence but not as 
high as for the first motif. The ScFv specific to the same peptides also gave high fluorescence when incubated 
with Nef-exosomes, even though the mean fluorescence was lower compared to antibodies bound to the 
infected cells (see Fig. 8e & D). We further confirmed these finding by first incubating the ScFv with peptides 
containing specific motifs and then incubating with the infected cells and/or Nef-exosomes. Pre-incubation with 
peptides resulted in disappearance of fluorescence suggested that ScFv were indeed binding specifically to the 
identified motifs. At this stage of the project, we successfully identified 4 Nef motifs that are exposed on the 
surface of HIV-1 infected cells and Nef-exosomes secreted by these cells. Now that the exposed motifs are 
identified we aim to et these motifs for ntial anti ediated thera 'c intervention. 
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METHODOLOGY ARTICLE Open Access 
Production and purification of polymerization-
competent HIV-l capsid protein p24 (CA) 
in NiCo2l (DE3) Escherichia coli 
Sin Yeang Teowlt, Siti Aisyah Mualiflt, Tasyriq Che Omar\ Chew Yik Weill Narazah Mohd Yusoff2 and Syed A Alt 
Abstract 
Background: HIV genome is packaged and organized in a conical capsid, which is made up of ~1,500 copies of 
the viral capsid protein p24 (CA). Being a primary structural component and due to its critical roles in both late and 
early stages of the HIV replication cycle, CA has attracted increased interest as a drug discovery target in recent 
years. Drug discovery studies require large amounts of highly pure and biologically active protein. It is therefore 
desirable to establish a simple and reproducible process for efficient production of HIV-l CA 
Result: In this work, 6-His-tagged wild type CA from HIV-l (NL4.3) was expressed in rare tRNA-supplemented 
NiC02l (DE3) Escherichia coli, and its production was studied in shake flask culture condition of expression. Influences 
of various key cultivation parameters were examined to identify optimal conditions for HIV-l CA production. It was 
found that a culture temperature of 22°C and induction with 0.05 mM IPTG at the early stage of growth were ideal, 
leading to a maximum biomass yield when grown in Super broth supplemented with 1% glucose. With optimized 
culture conditions, a final biomass concentration of ~27.7 g L- l (based on optical density) was obtained in 12 hours 
post-induction, leading to a yield of about ~170 mg L-l H1V-1 CA A two-step purification strategy (chitin beads + 
IM~q .Y'!as empl?xed, w.hich efficiently removed metal affinity resin-binding bacterial proteins that contaminate 
recombinant His-tagged protein preparation, and resulted Inhtgnlypure HW-l CAThe purified proteirYWas ccfpable . 
of polymerization when tested in an in vitro polymerization assay. 
Conclusions: By using this optimized expression and purification procedure, milligram amounts of highly pure 
and polymerization-competent recombinant HIV-l CA can be produced at the lab-scale and thus used for further 
biochemical studies. 
Background 
Human immunodeficiency virus (HIV) causes acquired 
immunodeficiency syndrome (AIDS), a progressive im-
mune disorder that allows life-threatening opportunistic 
infections, cardiovascular diseases, and cancers to thrive. 
The capsid protein p24 (CA) plays seminal roles in both 
late and early stages of the HIV replication cycle (1]. 
HIV-l CA is considered an important target for develop-
ing novel drugs to treat AIDS. For example, a small mole-
cule, CAP-I, and two versions of a peptide inhibitor, CAl 
and NYAD-l, have been reported that target HIV-l CA 
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in vitro and interfere with its fUnction in infected cells 
[2-4]. In another study, two small compounds PF-3450074 
and PF-3759857 have shown to be active against HIV-l in 
low 11M concentration and latter (PF-3759857) against 
HIV-2 too [5]. More recently, compounds derived from 
benzodiazepines (BD) and the benzimidazoles (BM) series 
of chemicals have shown to prevent virion release and 
inhibited the formation of the mature capsid [6). These 
studies require milligram quantities of the CA in soluble 
and active form. However, high commercial cost may limit 
its use in studies carried out at academic level. 
The HIV -1 CA has been produced in bacterium 
Escherichia coli [7-11], yeast Pichea pastoris [12], plants 
[13-15], and baculovirus-insect cells [16]. However, 
eXisting methodologies rely on sequence modifications 
and several purification rounds involving precipitation 
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